Progestin effects on cell proliferation pathways in the postmenopausal mammary gland

Breast Cancer Research

Volumn 15, Issue 4, 2013, Pages

  Wood, Charles E ^a   Branstetter, Daniel ^b   Jacob, Allison P ^b   Cline, J Mark ^a   Register, Thomas C ^a   Rohrbach, Kathy ^b   Huang, Li Ya ^b   Borgerink, Hermina ^a   Dougall, William C ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b AMGEN INC   (United States)

Author keywords

Breast cancer; Denosumab; Estrogen; Gene expression; Postmenopausal hormone therapy; Progestin; RANKL; Tibolone

Indexed keywords

AMPHIREGULIN; CONJUGATED ESTROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GESTAGEN; HYPOCALCIN; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; MONOCLONAL ANTIBODY KI 67; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SOMATOMEDIN BINDING PROTEIN 1; STAT5 PROTEIN; STAT5A PROTEIN; THROMBOSPONDIN; TIBOLONE; TRANSFORMING GROWTH FACTOR BETA; BIOLOGICAL MARKER; ESTROGEN; ESTROGEN RECEPTOR; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANTIBODY LABELING; ARTICLE; BREAST; BREAST EPITHELIUM; CANCER RISK; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; HORMONAL REGULATION; LOW DRUG DOSE; MACACA; MAMMARY GLAND; NONHUMAN; NUCLEOTIDE SEQUENCE; POSTMENOPAUSE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; ANIMAL; CLUSTER ANALYSIS; DRUG EFFECTS; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENETICS; HORMONE SUBSTITUTION; HUMAN; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; METABOLISM; UDDER;

ANIMALS; BIOLOGICAL MARKERS; CELL PROLIFERATION; CLUSTER ANALYSIS; EPITHELIAL CELLS; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; HORMONE REPLACEMENT THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; MACACA FASCICULARIS; MAMMARY GLANDS, ANIMAL; NORPREGNENES; POSTMENOPAUSE; PROGESTINS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 84881447455     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3456     Document Type: Article

References (53)

1. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004, 291:47-53. 10.1001/jama.291.1.47, 14709575.
2. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997, 89:1110-1116. 10.1093/jnci/89.15.1110, 9262248.
3. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397, Writing Group for the Women's Health Initiative Investigators.
4. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A. WHI Investigators Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003, 289:3243-3253. 10.1001/jama.289.24.3243, 12824205, WHI Investigators.
5. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL. WHI Investigators Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304:1684-1692. 10.1001/jama.2010.1500, 20959578, WHI Investigators.
6. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G. WHI Investigators Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009, 360:573-587. 10.1056/NEJMoa0807684, 19196674, WHI Investigators.
7. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Estrogen-progestin replacement and risk of breast cancer. JAMA 2000, 284:691-694.
8. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000, 92:328-332. 10.1093/jnci/92.4.328, 10675382.
9. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT. WHI Investigators Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006, 295:1647-1657. 10.1001/jama.295.14.1647, 16609086, WHI Investigators.
10. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, Margolis KL, Stefanick ML, Brzyski R, Curb JD, Howard BV, Lewis CE, Wactawski-Wende J. WHI Investigators Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011, 305:1305-1314. 10.1001/jama.2011.382, 3656722, 21467283, WHI Investigators.
11. Swanson SG, Drosman S, Helmond FA, Stathopoulos VM. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. Menopause 2006, 13:917-925. 10.1097/01.gme.0000247016.41007.c9, 17006377.
12. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R. LIFT Trial Investigators The effects of tibolone in older postmenopausal women. N Engl J Med 2008, 359:697-708. 10.1056/NEJMoa0800743, 3684062, 18703472, LIFT Trial Investigators.
13. Tang B, Markiewicz L, Kloosterboer HJ, Gurpide E. Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Mol Biol 1993, 45:345-351. 10.1016/0960-0760(93)90003-F, 8499344.
14. Genazzani AR, Benedek-Jaszmann LJ, Hart DM, Andolsek L, Kicovic PM, Tax L. Org OD 14 and the endometrium. Maturitas 1991, 13:243-251. 10.1016/0378-5122(91)90199-Z, 1943832.
15. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW. LIBERATE Study Group Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009, 10:135-146. 10.1016/S1470-2045(08)70341-3, 19167925, LIBERATE Study Group.
16. Ismail PM, Amato P, Soyal SM, DeMayo FJ, Conneely OM, O'Malley BW, Lydon JP. Progesterone involvement in breast development and tumorigenesis-as revealed by progesterone receptor " knockout" and " knockin" mouse models. Steroids 2003, 68:779-787. 10.1016/S0039-128X(03)00133-8, 14667968.
17. Pavlicek A, Noskov VN, Kouprina N, Barrett JC, Jurka J, Larionov V. Evolution of the tumor suppressor BRCA1 locus in primates: implications for cancer predisposition. Hum Mol Genet 2004, 13:2737-2751. 10.1093/hmg/ddh301, 15385441.
18. Cline JM, Wood CE. The mammary glands of macaques. Toxicol Pathol 2008, 36:134s-141s. 3070964, 21475638.
19. Wood CE, Usborne AL, Starost MF, Tarara RP, Hill LR, Wilkinson LM, Geisinger KR, Feiste EA, Cline JM. Hyperplastic and neoplastic lesions of the mammary gland in macaques. Vet Pathol 2006, 43:471-483. 10.1354/vp.43-4-471, 16846989.
20. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996, 174:93-100. 10.1016/S0002-9378(96)70379-4, 8572040.
21. Cline JM, Register TC, Clarkson TB. Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause 2002, 9:422-429. 10.1097/00042192-200211000-00007, 12439101.
22. Clarkson TB, Anthony MS, Wagner JD. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. J Clin Endocrinol Metab 2001, 86:5396-5404. 10.1210/jc.86.11.5396, 11701713.
23. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003, 19:368-375. 10.1093/bioinformatics/btf877, 12584122.
24. Wood CE, Kaplan JR, Fontenot MB, Williams JK, Cline JM. Endometrial profile of tamoxifen and low-dose estradiol combination therapy. Clin Cancer Res 2010, 16:946-956. 10.1158/1078-0432.CCR-09-1541, 2818660, 20103679.
25. Ma L, Hofling M, Masironi B, von Schoultz B, Cline JM, Sahlin L. Effects of tibolone and conventional HRT on the expression of estrogen and progesterone receptors in the breast. Maturitas 2008, 61:345-349. 10.1016/j.maturitas.2008.09.018, 18980817.
26. Santos SJ, Haslam SZ, Conrad SE. Signal transducer and activator of transcription 5a mediates mammary ductal branching and proliferation in the nulliparous mouse. Endocrinology 2010, 151:2876-2885. 10.1210/en.2009-1282, 2875824, 20392833.
27. Zhu J, Jia X, Xiao G, Kang Y, Partridge NC, Qin L. EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases. J Biol Chem 2007, 282:26656-26664. 10.1074/jbc.M705064200, 17636266.
28. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107. 10.1038/nature09495, 20881963.
29. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102. 10.1038/nature09387, 3084017, 20881962.
30. Fernandez-Valdivia R, Mukherjee A, Creighton CJ, Buser AC, DeMayo FJ, Edwards DP, Lydon JP. Transcriptional response of the murine mammary gland to acute progesterone exposure. Endocrinology 2008, 149:6236-6250. 10.1210/en.2008-0768, 2613059, 18687774.
31. Gonzalez-Suarez E, Branstetter D, Armstrong A, Dinh H, Blumberg H, Dougall WC. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol Cell Biol 2007, 27:1442-1454. 10.1128/MCB.01298-06, 1800710, 17145767.
32. Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, Yalcin-Ozuysal O, Brisken C. Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 2013, 5:182ra55. 10.1126/scitranslmed.3005654, 23616122.
33. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999, 84:4559-4565. 10.1210/jc.84.12.4559, 10599719.
34. Miyoshi K, Shillingford JM, Smith GH, Grimm SL, Wagner KU, Oka T, Rosen JM, Robinson GW, Hennighausen L. Signal transducer and activator of transcription (Stat) 5 controls the proliferation and differentiation of mammary alveolar epithelium. J Cell Biol 2001, 155:531-542. 10.1083/jcb.200107065, 2198867, 11706048.
35. Sternlicht MD. Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res 2006, 8:201. 10.1186/bcr1368, 1413974, 16524451.
36. Santos SJ, Haslam SZ, Conrad SE. Estrogen and progesterone are critical regulators of Stat5a expression in the mouse mammary gland. Endocrinology 2008, 149:329-338. 2194608, 17884938.
37. Kariagina A, Xie J, Leipprandt JR, Haslam SZ. Amphiregulin mediates estrogen, progesterone, and EGFR signaling in the normal rat mammary gland and in hormone-dependent rat mammary cancers. Horm Cancer 2010, 1:229-244. 10.1007/s12672-010-0048-0, 3000471, 21258428.
38. Nakashima T, Takayanagi H. Osteoimmunology: crosstalk between the immune and bone systems. J Clin Immunol 2009, 29:555-567. 10.1007/s10875-009-9316-6, 19585227.
39. Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012, 48:3082-3096. 10.1016/j.ejca.2012.08.002, 22975218.
40. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000, 103:41-50. 10.1016/S0092-8674(00)00103-3, 11051546.
41. Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery CA, Shyamala G, Conneely OM, O'Malley BW. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995, 9:2266-2278. 10.1101/gad.9.18.2266, 7557380.
42. Aupperlee MD, Drolet AA, Durairaj S, Wang W, Schwartz RC, Haslam SZ. Strain-specific differences in the mechanisms of progesterone regulation of murine mammary gland development. Endocrinology 2009, 150:1485-1494. 2654739, 18988671.
43. Beleut M, Rajaram RD, Caikovski M, Ayyanan A, Germano D, Choi Y, Schneider P, Brisken C. Two distinct mechanisms underlie progesterone-induced proliferation in the mammary gland. Proc Natl Acad Sci USA 2010, 107:2989-2994. 10.1073/pnas.0915148107, 2840294, 20133621.
44. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE. Control of mammary stem cell function by steroid hormone signalling. Nature 2010, 465:798-802. 10.1038/nature09027, 20383121.
45. Joshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD, Khokha R. Progesterone induces adult mammary stem cell expansion. Nature 2010, 465:803-807. 10.1038/nature09091, 20445538.
46. Russo IH, Russo J. Role of hormones in mammary cancer initiation and progression. J Mammary Gland Biol Neoplasia 1998, 3:49-61. 10.1023/A:1018770218022, 10819504.
47. Going JJ, Anderson TJ, Battersby S, MacIntyre CC. Proliferative and secretory activity in human breast during natural and artificial menstrual cycles. Am J Pathol 1988, 130:193-204. 1880536, 3337211.
48. Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab 2008, 93:3295-3298. 10.1210/jc.2008-0938, 2567860, 18647813.
49. Azim HA, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 2012, 18:1341-1351. 10.1158/1078-0432.CCR-11-2599, 22261811.
50. Wang J, Lee O, Heinz R, Ivancic D, Shcholtens D, Chatterton RT, Khan SA. Identification of hormone-responsive genes as biomarkers for menstrual cycle phases and menopausal status [abstract]. Cancer 2011, 71.
51. Srivastava S, Matsuda M, Hou Z, Bailey JP, Kitazawa R, Herbst MP, Horseman ND. Receptor activator of NF-kappaB ligand induction via Jak2 and Stat5a in mammary epithelial cells. J Biol Chem 2003, 278:46171-46178. 10.1074/jbc.M308545200, 12952963.
52. Buser AC, Gass-Handel EK, Wyszomierski SL, Doppler W, Leonhardt SA, Schaack J, Rosen JM, Watkin H, Anderson SM, Edwards DP. Progesterone receptor repression of prolactin/signal transducer and activator of transcription 5-mediated transcription of the beta-casein gene in mammary epithelial cells. Mol Endocrinol 2007, 21:106-125.
53. Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J, Kopchick JJ, Oka T, Kelly PA, Hennighausen L. Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev Biol 2001, 229:163-175. 10.1006/dbio.2000.9961, 11133161.